TW201713344A - 用於治療ｂ細胞惡性腫瘤之組合療法 - Google Patents

用於治療ｂ細胞惡性腫瘤之組合療法 Download PDF

Info

Publication number
TW201713344A
TW201713344A TW105119835A TW105119835A TW201713344A TW 201713344 A TW201713344 A TW 201713344A TW 105119835 A TW105119835 A TW 105119835A TW 105119835 A TW105119835 A TW 105119835A TW 201713344 A TW201713344 A TW 201713344A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
cell
acceptable salt
combination
Prior art date
Application number
TW105119835A
Other languages
English (en)
Chinese (zh)
Inventor
海倫 柯林斯
茱莉 蒂帕蘿
莎拉 麥兜
卡拉 奈森
凱西 基肯
小崎龍平
克里斯多弗 克法
斯里尼發山 拉曼那坦
史黛西 坦海莫
丹尼爾 杜馬斯
康廣朋子
吉澤敏男
Original Assignee
基利科學股份有限公司
小野藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 基利科學股份有限公司, 小野藥品工業股份有限公司 filed Critical 基利科學股份有限公司
Publication of TW201713344A publication Critical patent/TW201713344A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105119835A 2015-06-23 2016-06-23 用於治療ｂ細胞惡性腫瘤之組合療法 TW201713344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562183699P 2015-06-23 2015-06-23
US201562200610P 2015-08-03 2015-08-03
US201562263454P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
TW201713344A true TW201713344A (zh) 2017-04-16

Family

ID=56497846

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105119835A TW201713344A (zh) 2015-06-23 2016-06-23 用於治療ｂ細胞惡性腫瘤之組合療法

Country Status (5)

Country Link
US (1) US20180353512A1 (https=)
EP (1) EP3313405A1 (https=)
JP (1) JP6785804B2 (https=)
TW (1) TW201713344A (https=)
WO (1) WO2016209961A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
CA3101323A1 (en) * 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물
WO2023030437A1 (zh) * 2021-09-01 2023-03-09 江苏恒瑞医药股份有限公司 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途
CN114831991B (zh) * 2022-06-10 2024-02-06 陕西科技大学 Gsk2334470用于制备抗真菌药物及其增效剂的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
BR112012030711B1 (pt) * 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
DK2786996T3 (en) * 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
SG11201509842SA (en) * 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EA201691169A1 (ru) * 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2

Also Published As

Publication number Publication date
JP6785804B2 (ja) 2020-11-18
JP2018519300A (ja) 2018-07-19
WO2016209961A1 (en) 2016-12-29
EP3313405A1 (en) 2018-05-02
US20180353512A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
EP3355875B1 (en) Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
TW201639573A (zh) 有關治療癌症之合併治療
TW201609105A (zh) 治療骨髓增生失調之療法
TW201713344A (zh) 用於治療ｂ細胞惡性腫瘤之組合療法
TW201620519A (zh) 治療癌症之療法
AU2017305303B2 (en) Cobicistat for use in cancer treatments
US20180133212A1 (en) Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer
JP6815383B2 (ja) がん処置のための組み合わせ療法
OA18380A (en) Combination therapies for treating cancers.